2. Search Result
Search Result
Results for "

chorea

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-G0025
    Tetrabenazine Metabolite

    (-)-β-Dihydrotetrabenazine; (-)-β-HTBZ

    		 Monoamine Transporter Drug Metabolite Neurological Disease
    Tetrabenazine Metabolite is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite is a vesicular monoamine transporter 2 (VMAT2) inhibitor with a high affinity (Ki=13.4 nM) . Tetrabenazine Metabolite is be developed for the treatment of chorea associated with Huntington’s disease and other hyperkinetic disorders .
    Tetrabenazine Metabolite
  • HY-169728
    SID 24785302

    		Hexokinase Cardiovascular Disease Neurological Disease
    SID 24785302 is an inhibitor for hexokinase. SID 24785302 inhibits glycolysis, regulates mitochondrial functions, thereby inhibiting the replication of mutant mtDNA .
    SID 24785302
  • HY-158339
    ABHD antagonist 2

    		MAGL Neurological Disease
    ABHD antagonist 2 (Compound 9) is an antagonist for alpha/beta-Hydrolase domain containing 6 (ABHD6), with IC50 <0.001 μM. ABHD antagonist 2 exhibits good binding ability with ABHD6, with IC50 of 0.002 μM .
    ABHD antagonist 2
  • HY-141554A
    (2S,3S,11bR)-Dihydrotetrabenazine

    (2S,3S,11bR)-DHTBZ

    		 Monoamine Transporter Neurological Disease
    (2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. (2S,3S,11bR)-Dihydrotetrabenazine inhibits vesicular transport of monoamine neurotransmitters like dopamine and serotonin, reducing their synaptic release. (2S,3S,11bR)-Dihydrotetrabenazine is promising for research of Huntington's chorea and other hyperkinetic disorders .
    (2S,3S,11bR)-Dihydrotetrabenazine
  • HY-128128
    ASN04421891

    		Transmembrane Glycoprotein Cardiovascular Disease Neurological Disease Inflammation/Immunology
    ASN04421891 is a GPR17 agonist with nanomolar EC50 and high specificity. ASN04421891 promotes oligodendrocyte precursor cell maturation to mature myelinating oligodendrocytes. ASN04421891 can be used for the research of cerebral ischaemia, cardiac ischaemia, renal ischaemia, cerebral trauma, multiple sclerosis, schizophrenia, depression, alzheimer's disease, alzheimer-like dementia, parkinson's disease, huntington's chorea, amyotrophic lateral sclerosis (ALS), neuroinflammatory disorders .
    ASN04421891
  • HY-156505A
    R-(+)-EU-1180-453

    		iGluR Neurological Disease
    R-(+)-EU-1180-453 is a positive allosteric modulator targeting NMDA receptors containing GluN2C and GluN2D subunits, with a pEC50 value of 5.5 for both rat receptor subtypes, and it can cross the blood-brain barrier. R-(+)-EU-1180-453 increases the potency of glutamate, enhances receptor responses to maximally effective concentrations of agonists, and acts only on receptors bound to both co-agonists. R-(+)-EU-1180-453 is applicable to research related to Alzheimer's disease, Parkinson's disease, epilepsy, and neuropathic pain .
    R-(+)-EU-1180-453

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: